Perjeta

RBC Capital says the commercial opportunity for Puma Biotechnology Inc (NASDAQ: PBYI)’s breast cancer drug neratinib in the extended adjuvant setting should be “considered as eliminated,” given Roche Holding Ltd. (ADR) (OTC: RHHBY)’s positive top-line data for Perjeta....